Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept

Elena Generali, Greta Carrara, Marinos Kallikourdis, Gianluigi Condorelli, Alessandra Bortoluzzi, Carlo A. Scirè, Carlo Selmi

Research output: Contribution to journalArticlepeer-review

Abstract

To estimate biologic influence on heart failure (HF) risk in rheumatoid arthritis. Retrospective cohort (RECORD Study of Italian Society for Rheumatology) study on administrative healthcare databases. We identified 2527 patients treated with either etanercept (n = 1690) or abatacept (n = 837). HF incidence rate was higher in the abatacept cohort than in the etanercept cohort with a 2.38 (95% CI 1.08–5.27) crude competing risk HR (SHR) for abatacept of developing HF, not confirmed after adjustment for prespecified confounders (SHR 1.43; 95% CI 0.51–3.98). Abatacept, compared to etanercept, is prescribed to patients with a worse cardiovascular profile but does not increase the risk of developing HF, when confounding factors are accounted for.

Original languageEnglish
JournalRheumatology International
DOIs
Publication statusAccepted/In press - Jan 1 2018

Keywords

  • Biologic
  • Cardiovascular
  • DMARDs
  • Epidemiology

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept'. Together they form a unique fingerprint.

Cite this